Provided by Tiger Trade Technology Pte. Ltd.

Biogen

192.03
-0.0500-0.03%
Post-market: 192.030.00000.00%19:34 EST
Volume:799.23K
Turnover:153.20M
Market Cap:28.17B
PE:21.85
High:192.60
Open:190.78
Low:189.95
Close:192.08
52wk High:202.41
52wk Low:110.04
Shares:146.70M
Float Shares:146.23M
Volume Ratio:0.66
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.79
EPS(LYR):8.79
ROE:7.39%
ROA:6.14%
PB:1.54
PE(LYR):21.85

Loading ...

Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst

TIPRANKS
·
Yesterday

Biogen Initiated at Equal-Weight by Barclays

Dow Jones
·
Feb 20

Biogen Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Feb 20

Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism

Simply Wall St.
·
Feb 19

Nicole Murphy, Head of Pharm Ops and Tech, acquires Biogen Inc. common shares

Reuters
·
Feb 18

Biogen’s New Therapies Surpass US$1 Billion In Sales Might Change The Case For Investing In BIIB

Simply Wall St.
·
Feb 15

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Simply Wall St.
·
Feb 13

Biogen (BIIB) Valuation Check After Q4 Beat And Momentum In New Drugs Like Leqembi

Simply Wall St.
·
Feb 12

Biogen Announces Board Chair Caroline Dorsa to Step Down

TIPRANKS
·
Feb 12

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 12

Biogen Elects Maria C. Freire as New Board Chair

Reuters
·
Feb 12

Biogen: Freire Will Succeed Caroline Dorsa

THOMSON REUTERS
·
Feb 12

Biogen Announces Board Chair Transition

THOMSON REUTERS
·
Feb 12

Biogen: Elected DR. Maria C. Freire as Chair of Board of Directors

THOMSON REUTERS
·
Feb 12

Biogen Is Maintained at Neutral by Wedbush

Dow Jones
·
Feb 10

Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point

Simply Wall St.
·
Feb 10

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Feb 10

Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says

MT Newswires Live
·
Feb 10

Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'

Benzinga_recent_news
·
Feb 09

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Benzinga
·
Feb 09